Condition: Alzheimers Disease · Dementia · Alzheimers Disease, Familial · Sponsor: Washington University School of Medicine
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama in Birmingham | Birmingham, Alabama, United States | — |
| University of California San Diego Medical Center | La Jolla, California, United States | — |
| USC Keck School of Medicine | Los Angeles, California, United States | — |
| Yale University School of Medicine | New Haven, Connecticut, United States | — |
| Emory University | Atlanta, Georgia, United States | — |
| Advocate Lutheran General Hospital | Park Ridge, Illinois, United States | — |
| Indiana University School of Medicine | Indianapolis, Indiana, United States | — |
| Washington University in St. Louis | St Louis, Missouri, United States | — |
| University of Pittsburgh | Pittsburgh, Pennsylvania, United States | — |
| Butler Hospital | Providence, Rhode Island, United States | — |
| Kerwin Medical Center | Dallas, Texas, United States | — |
| University of Washington | Seattle, Washington, United States | — |
+ 26 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.